MENU
+Compare
ATXS
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$7.50
Change
-$0.25 (-3.23%)
Capitalization
423.26M

ATXS Astria Therapeutics Forecast, Technical & Fundamental Analysis

a developer of new medicines for the treatment of cardiovascular, metabolic and inflammatory diseases

Industry Biotechnology
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ATXS with price predictions
Jan 08, 2025

ATXS in -5.57% downward trend, sliding for three consecutive days on January 06, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ATXS declined for three days, in of 321 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis
Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for ATXS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ATXS advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

ATXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.718) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). ATXS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (264.084).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ATXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ATXS is expected to report earnings to rise 7.62% to -45 cents per share on March 06

Astria Therapeutics ATXS Stock Earnings Reports
Q4'24
Est.
$-0.45
Q3'24
Est.
$-0.42
Q2'24
Missed
by $0.06
Q1'24
Missed
by $0.03
Q4'23
Missed
by $0.08
The last earnings report on November 13 showed earnings per share of -41 cents, meeting the estimate of -41 cents. With 237.44K shares outstanding, the current market capitalization sits at 423.26M.
A.I. Advisor
published General Information

General Information

a developer of new medicines for the treatment of cardiovascular, metabolic and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
75 State Street
Phone
+1 617 349-1971
Employees
59
Web
https://www.astriatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JSGAX27.200.30
+1.12%
JHancock U.S. Growth A
SCIEX17.970.09
+0.50%
Hartford Schroders International Stk I
HDCVX15.050.03
+0.20%
Janus Henderson Responsible Intl Div C
MNOZX32.75N/A
N/A
Manning & Napier Overseas Series Z
GEPPX9.85N/A
N/A
Goldman Sachs ESG Em Mkts Eq P

ATXS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KYMR. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-3.23%
KYMR - ATXS
45%
Loosely correlated
+0.79%
IMNM - ATXS
44%
Loosely correlated
+1.32%
KALV - ATXS
44%
Loosely correlated
+0.61%
ORIC - ATXS
42%
Loosely correlated
-4.58%
ACLX - ATXS
42%
Loosely correlated
-0.79%
More